Elite Pharmaceuticals, Inc., a health care company specializing in the research, development, licensing, and manufacturing of both new and generic oral controlled-release pharmaceutical products, has recently provided an update on its corporate activities. Based in Northvale, United States, the company operates within the Pharmaceuticals sector of the Health Care industry and is listed on the OTC Bulletin Board under the ticker symbol ELIT.
As of February 12, 2026, Elite Pharmaceuticals’ stock closed at $0.44 per share. This price is notably below the company’s 52-week low of $0.27, recorded on April 6, 2025, but remains within the range of its 52-week high of $0.82, achieved on June 17, 2025. The current market capitalization stands at approximately $473.83 million USD, reflecting the company’s valuation in the market.
The company’s financial metrics reveal a price-to-earnings (P/E) ratio of 33.84, indicating that the market values the firm at a multiple of its earnings that is higher than typical industry averages. Additionally, the price-to-book ratio is 7.81115, further suggesting a premium valuation relative to the company’s book value.
Elite Pharmaceuticals is actively engaged in developing pain products that are currently in clinical trials. The company’s portfolio includes therapeutic agents targeting cardiovascular, antidiabetic, and anti-infective conditions, as well as cough and cold preparations. These efforts underscore the company’s commitment to expanding its range of pharmaceutical offerings.
The most recent corporate update from Elite Pharmaceuticals was delivered through a conference call scheduled for February 18, 2026, following a news release dated February 11, 2026. This update provides stakeholders with insights into the company’s ongoing projects and strategic direction.
For more detailed information about Elite Pharmaceuticals’ activities and product offerings, interested parties are encouraged to visit the company’s website at www.elitepharma.com .
In summary, Elite Pharmaceuticals, Inc. continues to navigate the competitive landscape of the pharmaceutical industry with a focus on innovative product development and strategic growth initiatives. The company’s recent financial performance and market valuation metrics reflect its ongoing efforts to enhance shareholder value and expand its market presence.
